Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid …
TC Chua, TD Yan, A Saxena, DL Morris - Annals of surgery, 2009 - journals.lww.com
Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy
(HIPEC) has been offered in many institutions worldwide since the 1990s. Despite its …
(HIPEC) has been offered in many institutions worldwide since the 1990s. Despite its …
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis
JH Helm, JT Miura, JA Glenn, RK Marcus… - Annals of surgical …, 2015 - Springer
Background Due to the increased adoption of cytoreductive surgery (CRS) and hyperthermic
intraperitoneal chemotherapy (HIPEC), patients with malignant peritoneal mesothelioma …
intraperitoneal chemotherapy (HIPEC), patients with malignant peritoneal mesothelioma …
Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a …
O Glehen, FN Gilly, F Boutitie, JM Bereder, F Quenet… - Cancer, 2010 - Wiley Online Library
BACKGROUND: Peritoneal carcinomatosis (PC) from nonovarian malignancies long has
been regarded as a terminal disease. Over the past decade, new locoregional therapeutic …
been regarded as a terminal disease. Over the past decade, new locoregional therapeutic …
Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal …
Background Peritoneal carcinomatosis (PC) from gastric cancer has long been regarded a
terminal disease with a short median survival. New locoregional therapeutic approaches …
terminal disease with a short median survival. New locoregional therapeutic approaches …
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival
F Baumann, E Flores, A Napolitano, S Kanodia… - …, 2015 - academic.oup.com
Abstract BRCA1-associated protein-1 (BAP1) mutations cause a new cancer syndrome, with
a high rate of malignant mesothelioma (MM). Here, we tested the hypothesis that MM …
a high rate of malignant mesothelioma (MM). Here, we tested the hypothesis that MM …
Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis
YR Huo, A Richards, W Liauw, DL Morris - European Journal of Surgical …, 2015 - Elsevier
Purpose Emerging evidence suggests that hyperthermic intraperitoneal chemotherapy
(HIPEC) with cytoreductive surgery (CRS) shows a survival benefit over CRS alone for …
(HIPEC) with cytoreductive surgery (CRS) shows a survival benefit over CRS alone for …
[HTML][HTML] Hyperthermic intraperitoneal chemotherapy: rationale and technique
S González-Moreno, LA González-Bayón… - World journal of …, 2010 - ncbi.nlm.nih.gov
The combination of complete cytoreductive surgery and perioperative intraperitoneal
chemotherapy provides the only chance for long-term survival for selected patients …
chemotherapy provides the only chance for long-term survival for selected patients …
A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer
TD Yan, D Black, PH Sugarbaker, J Zhu… - Annals of surgical …, 2007 - Springer
Background The purpose of this systematic review and meta-analysis was to determine the
effectiveness and safety of adjuvant intraperitoneal chemotherapy for patients with locally …
effectiveness and safety of adjuvant intraperitoneal chemotherapy for patients with locally …
Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results
TC Chua, G Robertson, W Liauw, R Farrell… - Journal of cancer …, 2009 - Springer
Background Advanced and recurrent ovarian cancer results in extensive spread of tumor on
the peritoneal surfaces of the abdomen and pelvis. We collectively review studies in the …
the peritoneal surfaces of the abdomen and pelvis. We collectively review studies in the …
Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence
WP Ceelen, MF Flessner - Nature reviews Clinical oncology, 2010 - nature.com
In patients with tumors confined to the peritoneal cavity, there is established
pharmacokinetic and tumor biology-related evidence that intraperitoneal drug administration …
pharmacokinetic and tumor biology-related evidence that intraperitoneal drug administration …